Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 1;42(1):32-34.
doi: 10.1097/INF.0000000000003740. Epub 2022 Oct 21.

Monoclonal Antibody and Antiviral Therapy for Mild-to-Moderate COVID-19 in Pediatric Patients

Surabhi B Vora  1 , Janet A Englund  1 , Indi Trehan  1 , Alpana Waghmare  1 , Ada Kong  2 , Amanda Adler  3 , Danielle M Zerr  1
Affiliations

Monoclonal Antibody and Antiviral Therapy for Mild-to-Moderate COVID-19 in Pediatric Patients

Surabhi B Vora et al. Pediatr Infect Dis J. .

Abstract

Multiple antiviral and monoclonal antibody therapies are now available for mild-moderate COVID-19 in high-risk patients ≥12 years of age. However, data for the use of these agents in children is limited. We reviewed 94 pediatric patients for whom early therapy was requested since the emergence of the Omicron variant and describe patient characteristics, treatment logistics and associated short-term events.

PubMed Disclaimer

Conflict of interest statement

J.A.E. receives research support from AstraZeneca and Pfizer and is a consultant for AstraZeneca, Moderna and Meissa Vaccines. A.W. reports grant support from Ansun Biopharma, Allovir, GSK/Vir, and Pfizer and is an Advisory Board Member for Kyorin Pharmaceutical. All other authors have no conflicts of interest relevant to this work to disclose.

References

    1. Gandhi RT, Malani PN, del Rio C. COVID-19 Therapeutics for nonhospitalized patients. JAMA. 2022;327:617–618. - PubMed
    1. Hammond J, Leister-Tebbe H, Gardner A, et al. . Oral nirmatrelvir for high-risk nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397–1408. - PMC - PubMed
    1. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. . Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:21. - PubMed
    1. Gottlieb RL, Vaca CE, Paredes R, et al. . Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386:305–315. - PMC - PubMed
    1. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Lagevrio (molnupiravir) Capsules. August 2022. Available at: https://www.fda.gov/media/155054/download. Accessed September 7, 2022.

Supplementary concepts